Oxford PharmaGenesis™ will be showcasing its new HealthScience approach to demonstrating product value and achieving market access at ISPOR’s 19th Annual International Meeting in Montreal, Canada (31 May–4 June 2014).
HealthScience integrates the clinical and scientific dimensions of health care with the economic, social, behavioural and political perspectives that play a key role in determining the value of new medicines and health interventions. “It is no longer enough to show that a new treatment is effective and safe,” says Dr Chris Winchester, Managing Director of Oxford PharmaGenesis™. “It must now also be cost-effective, and it must meet the expectations of patients and society.”
“We have a powerful concept here,” said Dr Richard White, Commercial Director. “Our ideal is for HealthScience to be accepted as the standard approach to demonstrating the value of new therapies.”
A team of expert consultants from Oxford PharmaGenesis™ – Richard White, Karen Smoyer Tomic, Cate Scott, Rowena Hughes, Kate Young and Gordon Muir-Jones – will be available at Booths 122/123, Palais des congrès de Montréal, to discuss how HealthScience can be used to optimize patient access in global healthcare systems.
